Anthony Scaramucci Supports David Bailey Amid NAKA Stock Volatility

Anthony Scaramucci supports David Bailey, founder of Kindly MD Inc. (NAKA), despite the company's poor stock performance. Bailey admits that investors are down money, but is confident of a comeback. NAKA shares have crashed over 50% and Bailey advises investors who came for a trade to exit. Scaramucci says "all will be well."

Kindly MD Inc. (NAKA), a hybrid healthcare and Bitcoin treasury company, has been facing significant challenges since its merger with Nakamoto Holdings in 2025. The company's stock has experienced a sharp decline, with shares crashing over 50% following a large private investment in public equity (PIPE) share release tied to an S-3 registration. This event has driven heavy selling pressure and raised concerns among investors about the company's future prospects.

David Bailey, the CEO of Kindly MD Inc., has urged short-term traders to exit their positions, citing alignment and potential volatility during the transition to a Bitcoin treasury model. Bailey acknowledges that investors are down money but remains confident in the company's long-term potential. Anthony Scaramucci, a prominent investor and former White House communications director, has expressed support for Bailey, stating that "all will be well."

The regulatory environment has also posed challenges for NAKA. In September 2025, the Nasdaq started tightening oversight on crypto treasury companies, requiring shareholder approval before buying cryptocurrencies. This update aims to ensure investors are fully informed and consenting when public companies pursue crypto accumulation strategies. NAKA's stock tumbled as investors reassessed the viability of its Bitcoin treasury goals, as the company's market value is largely tied to Bitcoin accumulation.

NAKA's valuation remains a contentious issue. The company trades at a $3.0 billion market cap, with a pro-forma balance sheet indicating approximately $1.05 billion in assets, $199.46 million in liabilities, and $850.54 million in book value. However, the company's valuation metrics, such as a 3.5 price-to-book ratio (P/B) and a very expensive price-to-sales ratio (P/S) of 1500, suggest that NAKA is considerably more expensive than its peers like Strategy Inc. (MSTR).

In conclusion, Kindly MD Inc. (NAKA) is navigating a complex regulatory landscape and facing significant stock volatility. While the company's long-term ambitions remain intact, the immediate challenges and regulatory hurdles may continue to weigh on its stock performance. Investors should closely monitor the company's progress and the evolving regulatory environment.